Clinical Trials
102 trialsTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors
University of Southern California
STARTRK-2
Hoffmann-La Roche
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Children's Oncology Group
CER
Cancer Support Community, Research and Training Institute, Philadelphia
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
National Institutes of Health Clinical Center (CC)
SURGE
Colorado State University
Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members
M.D. Anderson Cancer Center
DETERMINE
Cancer Research UK
MK-3475-D20
BioInvent International AB
SELECT-CAR-NK
Essen Biotech
IT-TCP POS
Azienda Ospedaliero-Universitaria di Parma
PREPARE
Institut Bergonié
CAMPERR
Adela, Inc
Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers
Memorial Sloan Kettering Cancer Center
LIBERATE
University Health Network, Toronto
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
AVM Biotechnology Inc
EARN
Washington University School of Medicine
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Incyte Corporation
PRIORITY
Institut Bergonié
AMPLIFY
University of Alabama at Birmingham
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
Improved Early Diagnosis in Female Pelvic Cancer With OC Detect
Region Skane
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Seagen Inc.
MOHCCN-O
University Health Network, Toronto
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Cyteir Therapeutics, Inc.
ROOT
Taproot Health
QUANTUM
VitaMed Research LLC
Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies
ModernaTX, Inc.
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Sanguine Biosciences
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Celldex Therapeutics
AcSé
UNICANCER
Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma
Stingthera, Inc.
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Corvus Pharmaceuticals, Inc.
ALpha-T
Hoffmann-La Roche
Comparative Effectiveness Analysis of Granulocyte Colony Stimulating Factor Originator Products Versus Biosimilars
Biologics & Biosimilars Collective Intelligence Consortium
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
City of Hope Medical Center
Follow-up Protocol for Patients With Cancer/AIDS/Skin Disease
National Institutes of Health Clinical Center (CC)
An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
Eisai Inc.
Mini-allo
Scripps Health
RESTORE
Blue Note Therapeutics
SPACE2
Weprom
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
Incyte Corporation
ONCOPRO
Hospices Civils de Lyon
AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas
AstraZeneca
HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life
University Hospital Southampton NHS Foundation Trust
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Incyte Corporation